Gilde Healthcare company GT Medical Technologies raises $37 million in to advance GammaTile® for patients with operable brain tumors - Gilde Healthcare

Gilde Healthcare company GT Medical Technologies raises $37 million in to advance GammaTile® for patients with operable brain tumors

17 januari 2025
Tempe, Arizona (United States)

GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced the company has completed a $37 million first close of a Series D financing round.

The financing was led by Evidity Health Capital, alongside new investor Accelmed Partners. Also participating were existing investors Gilde Healthcare, MVM Partners, and Medtech Venture Partners. The funds will accelerate the completion of the ROADS clinical study that is focused on GammaTile for newly diagnosed brain metastases, and the GESTALT clinical trial for patients with newly diagnosed glioblastomas (GBMs). In addition, the funds will support the continued commercialization of GammaTile®, the Company’s FDA cleared bioresorbable radiotherapy implant for the treatment of brain tumors.

By delivering tile-based radiation therapy directly into the surgical cavity at the time of tumor removal, GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are at their lowest levels to help prevent regrowth while minimizing radiation exposure to healthy brain tissue.

About GT Medical Technologies, Inc.
GT MedTech was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.

About GammaTile®
Since its initial market release in the United States in January 2019, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com and follow @GammaTile on Facebook, Instagram, LinkedIn and X.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Meer nieuws

Gilde Healthcare lanceert Climate Solutions fonds en haalt €250 mln op

Met commitments van internationale pensioenfondsen, banken, fund-of-funds, endowments en family offices realiseert Gilde Healthcare een eerste closing van €250 miljoen Uitbreiding naar Climate Solutions bouwt voort op Gilde Healthcare’s track-record in impactvol investeren en rapportage...
18 februari 2026

Gilde Healthcare Company Big Health Secures Funding to Accelerate Adoption of Digital Mental Health Treatments

New investment fuels expansion as leading health systems adopt evidence-based digital care, driven by new billing codes and strong demand for proven mental health solutions. Big Health, a leading developer of digital treatments for the...
12 februari 2026

Gilde Healthcare company SpyGlass Pharma announces pricing of initial public offering at NASDAQ

SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per...
6 februari 2026